NAVCO Pharmaceuticals (DB:F0U) - Stock Price, News & Analysis

F0U Stock Overview

Researches, develops, manufactures, and commercializes nanotechnology products and materials. More details

F0U fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	1/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (2.3x) is below the German market (15.5x)

Became profitable this year

Risk Analysis

Makes less than USD$1m in revenue (CA$0)

Debt is not well covered by operating cash flow

High level of non-cash earnings

Does not have a meaningful market cap (€1M)

+ 2 more risks

NAVCO Pharmaceuticals Inc. Competitors

Epigenomics

DB:ECX

€875.2k

Enzon Pharmaceuticals

OTCPK:ENZN

US$5.3m

2invest

XTRA:2INV

€63.8m

Hindustan Bio Sciences

BSE:532041

₹102.5m

Price History & Performance

Summary of all time highs, changes and price drops for NAVCO Pharmaceuticals
Historical stock prices
Current Share Price	CA$0.015
52 Week High	CA$0.099
52 Week Low	CA$0.013
Beta	0
11 Month Change	-38.78%
3 Month Change	-50.00%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-44.85%

Recent updates

Shareholder Returns

	F0U	DE Biotechs	DE Market
7D	3.4%	0.8%	-1.3%
1Y	n/a	-17.5%	7.4%

Return vs Industry: Insufficient data to determine how F0U performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how F0U performed against the German Market.

Price Volatility

Is F0U's price volatile compared to industry and market?
F0U volatility
F0U Average Weekly Movement	86.0%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: F0U's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: F0U's weekly volatility has increased from 68% to 86% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Geoffrey Lee	navcopharma.com

NAVCO Pharmaceuticals Inc. researches, develops, manufactures, and commercializes nanotechnology products and materials. It offers aerosol spray, hand cream and sanitizer, and colloidal silver products. The company also provides COVID PCR testing, PPE, and diagnostic PCR testing, as well as textile and food solutions.

NAVCO Pharmaceuticals Inc. Fundamentals Summary

How do NAVCO Pharmaceuticals's earnings and revenue compare to its market cap?
F0U fundamental statistics
Market cap	€779.55k
Earnings (TTM)	€334.19k
Revenue (TTM)	n/a

2.3x

P/E Ratio

0.0x

P/S Ratio

Is F0U overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
F0U income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	-CA$489.32k
Earnings	CA$489.32k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.0086
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	3,488.3%

How did F0U perform over the long term?

See historical performance and comparison

NAVCO Pharmaceuticals DB:F0U Stock Report